Efficacy and Safety of Cyclophosphamide in Amyotrophic Lateral Sclerosis (CORTEX-ALS)

September 16, 2026 updated by: Xiangjun Chen, Huashan Hospital

Efficacy and Safety of Cyclophosphamide in Amyotrophic Lateral Sclerosis: A Multicenter, Open-Label, Randomized, Parallel-Controlled Trial With Blinded Endpoint Assessment (CORTEX-ALS)

The goal of this clinical trial is to learn whether cyclophosphamide (CTX) combined with standard treatment can slow disease progression in adults with amyotrophic lateral sclerosis (ALS). It will also evaluate the safety and tolerability of CTX. The main questions it aims to answer are:

  1. Does CTX combined with standard treatment reduce the decline in ALS Functional Rating Scale-Revised (ALSFRS-R) scores over 48 weeks compared with standard treatment alone?
  2. What medical problems and side effects do participants have while receiving CTX?
  3. Are markers of neuroinflammation and immune activity, including TSPO-PET, neurofilament light chain (NfL), upper motor neuron burden, electrophysiological measures, immune cell profiles, and autoantibodies, associated with treatment response?

Researchers will compare CTX combined with standard treatment with standard treatment alone to see whether CTX can slow the progression of ALS.

Participants will:

  1. Be randomly assigned to receive CTX plus standard treatment or standard treatment alone
  2. Receive CTX treatment for up to 36 weeks if assigned to the CTX group
  3. Visit the study center regularly for clinical assessments, blood tests, lung function tests, electrophysiological tests, and other safety evaluations
  4. Complete assessments of physical function, muscle strength, respiratory function, and quality of life
  5. Undergo biomarker assessments, including TSPO-PET imaging and NfL testing
  6. Be followed for 48 weeks during the main study period and for up to 96 weeks for long-term outcomes and safety

Study Overview

Status

Not yet recruiting

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 18 to 75 years.
  • Diagnosis of amyotrophic lateral sclerosis (ALS) according to the 2020 revised Gold Coast diagnostic criteria, confirmed by an ALS specialist at a participating study center.
  • A decline of 1 to 4 points in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) during the 12-week observation period before randomization.
  • Time from symptom onset to randomization ≤2 years.
  • Positive TSPO-PET confirmed by the central imaging core laboratory.
  • Each ALSFRS-R item score ≥2 at baseline; the dyspnea, orthopnea, and respiratory insufficiency items must each have a score of 4.
  • Baseline forced vital capacity (FVC) ≥70% of the predicted value.
  • Willing and able to comply with study treatment and follow-up procedures and provide written informed consent, including informed consent for off-label use of cyclophosphamide.

Exclusion Criteria:

  • Presence of an ALS mimic or another condition that better explains the clinical presentation, including multifocal motor neuropathy, motor-predominant chronic inflammatory demyelinating polyneuropathy, cervical spinal cord compression, Kennedy disease, hereditary spastic paraplegia, myasthenia gravis, inclusion body myositis, or metabolic, infectious, or paraneoplastic disorders.
  • Motor conduction block or clinically significant sensory nerve conduction abnormalities on nerve conduction studies.
  • Systemic autoimmune disease, such as systemic lupus erythematosus, rheumatoid arthritis, or Sjögren syndrome, requiring systemic immunosuppressive therapy.
  • Familial ALS, or a defined genetic ALS subtype such as SOD1-associated ALS currently receiving gene-targeted therapy or participating in another investigational drug trial.
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the upper limit of normal, or serum creatinine above the upper limit of normal.
  • Active infection, or uncontrolled hepatitis B virus infection, hepatitis C virus infection, human immunodeficiency virus infection, or active tuberculosis identified during screening.
  • White blood cell count <3.5 × 10^9/L, absolute neutrophil count <1.5 × 10^9/L, platelet count <100 × 10^9/L, or hemoglobin <90 g/L.
  • Severe concomitant neurological, cardiovascular, pulmonary, renal, hematologic, endocrine, or psychiatric disease that, in the investigator's judgment, may interfere with study participation or safety.
  • Suspected or confirmed history of alcohol or drug abuse.
  • Pregnancy or breastfeeding, or unwillingness of participants of reproductive potential to use effective contraception.
  • Known hypersensitivity to cyclophosphamide.
  • Participation in another interventional clinical trial within 3 months before screening.
  • Baseline imaging data of inadequate quality for analysis, including severe motion artifacts or incorrect acquisition parameters.
  • Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study, including poor adherence or a high likelihood of loss to follow-up.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cyclophosphamide Plus Standard Treatment

Cyclophosphamide will be administered intravenously for 36 weeks in addition to standard treatment with riluzole. During the induction phase, participants will receive a total dose of 2.0 g over approximately 2 weeks in four divided infusions (400 mg, 600 mg, 400 mg, and 600 mg), with an interval of 1-2 days between infusions. During the maintenance phase, cyclophosphamide 1.0 g will be administered intravenously every 4 weeks through Week 36, for a planned cumulative dose of approximately 10.0 g. Hydration, mesna, and antiemetic treatment will be provided as appropriate. Dose delay, dose reduction, or permanent discontinuation will be permitted for treatment-related toxicity according to the study protocol.

Riluzole will be administered orally at a dose of 50 mg twice daily as standard treatment for amyotrophic lateral sclerosis. Participants should be receiving a stable dose before randomization and will continue treatment during the study unless dose modification or discontinuation is required for safety or tolerability reasons.

Active Comparator: Standard Treatment Alone

Riluzole will be administered orally at a dose of 50 mg twice daily as standard treatment for amyotrophic lateral sclerosis. Participants should be receiving a stable dose before randomization and will continue treatment during the study unless dose modification or discontinuation is required for safety or tolerability reasons.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score at Week 48
Time Frame: Baseline to Week 48

The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) is a 12-item scale used to assess functional impairment in participants with amyotrophic lateral sclerosis. Each item is scored from 0 to 4, yielding a total score ranging from 0 to 48. Higher total scores indicate better functional status, whereas lower scores indicate greater functional impairment. The outcome measure is the change in ALSFRS-R total score from baseline to Week 48, calculated as the Week 48 score minus the baseline score. A more negative change indicates greater functional decline.

Baseline to Week 48

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) Score at Week 48
Time Frame: Baseline to Week 48

The Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) is a 28-item patient-reported scale used to assess overall disability in participants with amyotrophic lateral sclerosis. Each item is scored from 0 to 2, yielding a raw total score ranging from 0 to 56. The raw score is converted to a linearly weighted normed ROADS score ranging from 0 to 120, with higher scores indicating better functional status and lower scores indicating greater disability. The outcome measure is the change in the normed ROADS score from baseline to Week 48, calculated as the Week 48 score minus the baseline score. A more negative change indicates greater functional decline.

Baseline to Week 48
Change From Baseline in Dominant Hand Grip Strength at Week 48
Time Frame: Baseline to Week 48
Baseline to Week 48
Change From Baseline in Percent-Predicted Forced Vital Capacity (FVC) at Week 48
Time Frame: Baseline to Week 48

Forced vital capacity (FVC) will be measured using standardized pulmonary function testing procedures and expressed as a percentage of the predicted value based on appropriate reference equations. The outcome measure is the change in percent-predicted FVC from baseline to Week 48, calculated as the Week 48 value minus the baseline value. A greater decrease indicates greater deterioration in respiratory function.

Baseline to Week 48
Change From Baseline in Neurofilament Light Chain (NfL) Levels at Week 48
Time Frame: Baseline to Week 48
Baseline to Week 48
Change From Baseline in Compound Muscle Action Potential (CMAP) Amplitude at Week 48
Time Frame: Baseline to Week 48

Compound muscle action potential (CMAP) amplitude will be assessed using standardized motor nerve conduction studies. CMAP amplitude will be measured in millivolts (mV). The outcome measure is the change in CMAP amplitude from baseline to Week 48, calculated as the Week 48 value minus the baseline value. A greater reduction in CMAP amplitude indicates greater loss of functional motor axons.

Baseline to Week 48
Change From Baseline in Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Score at Week 48
Time Frame: Baseline to Week 48
Baseline to Week 48
Time to Death, Enteral Feeding, or Permanent Assisted Ventilation
Time Frame: Randomization through Week 48
Randomization through Week 48
Change From Baseline in Percent-Predicted Slow Vital Capacity (SVC) at Week 48
Time Frame: Baseline to Week 48

Slow vital capacity (SVC) will be measured using standardized pulmonary function testing procedures and expressed as a percentage of the predicted value based on appropriate reference equations. The outcome measure is the change in percent-predicted SVC from baseline to Week 48, calculated as the Week 48 value minus the baseline value. A greater decrease indicates greater deterioration in respiratory function.

Baseline to Week 48
Change From Baseline in Motor Evoked Potential (MEP) Amplitude at Week 48
Time Frame: Baseline to Week 48

Motor evoked potential (MEP) amplitude will be assessed using standardized transcranial magnetic stimulation and neurophysiological recording procedures. MEP amplitude will be measured in millivolts (mV). The outcome measure is the change in MEP amplitude from baseline to Week 48, calculated as the Week 48 value minus the baseline value.

Baseline to Week 48

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in ALSFRS-R Total Score at Week 96
Time Frame: Baseline to Week 96

The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) is a 12-item scale used to assess functional impairment in participants with amyotrophic lateral sclerosis. Each item is scored from 0 to 4, yielding a total score ranging from 0 to 48. Higher total scores indicate better functional status, whereas lower scores indicate greater functional impairment. The outcome measure is the change in ALSFRS-R total score from baseline to Week 48, calculated as the Week 48 score minus the baseline score. A more negative change indicates greater functional decline.

Baseline to Week 96
Change From Baseline in Percent-Predicted Forced Vital Capacity (FVC) at Week 96
Time Frame: Baseline to Week 96

Forced vital capacity (FVC) will be measured using standardized pulmonary function testing procedures and expressed as a percentage of the predicted value based on appropriate reference equations. The outcome measure is the change in percent-predicted FVC from baseline to Week 96, calculated as the Week 96 value minus the baseline value. A greater decrease indicates greater deterioration in respiratory function.

Baseline to Week 96
Change From Baseline in King's College Clinical Staging System Stage Through Week 96
Time Frame: Baseline through Week 96

Disease progression will be assessed using the King's College Clinical Staging System for amyotrophic lateral sclerosis. The system classifies disease progression according to the number of central nervous system regions involved and the occurrence of nutritional or respiratory failure. Stages range from Stage 1 to Stage 4, with Stage 4 subdivided into Stage 4A (nutritional failure) and Stage 4B (respiratory failure). Higher stages indicate more advanced disease. Change in King's College Clinical Stage from baseline through Week 96 will be evaluated.

Baseline through Week 96
Change From Baseline in Amyotrophic Lateral Sclerosis Milano-Torino Staging (ALS-MiToS) System Stage Through Week 96
Time Frame: Baseline through Week 96

Disease progression will be assessed using the Amyotrophic Lateral Sclerosis Milano-Torino Staging (ALS-MiToS) System, which is based on loss of independence in four functional domains derived from the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): walking/self-care, swallowing, communicating, and breathing. Stages range from 0 to 5. Stage 0 indicates no loss of independence in any domain; Stages 1 through 4 indicate loss of independence in one to four domains, respectively; and Stage 5 indicates death. Higher stages indicate more advanced disease and greater loss of functional independence. Change in ALS-MiToS stage from baseline through Week 96 will be evaluated.

Baseline through Week 96
Time to Death or Permanent Assisted Ventilation Through Week 96
Time Frame: Randomization through Week 96
Randomization through Week 96
Change From Baseline in Percent-Predicted Slow Vital Capacity (SVC) at Week 96
Time Frame: Baseline to Week 48

Slow vital capacity (SVC) will be measured using standardized pulmonary function testing procedures and expressed as a percentage of the predicted value based on appropriate reference equations. The outcome measure is the change in percent-predicted SVC from baseline to Week 96, calculated as the Week 96 value minus the baseline value. A greater decrease indicates greater deterioration in respiratory function.

Baseline to Week 48

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 1, 2026

Primary Completion (Estimated)

October 30, 2028

Study Completion (Estimated)

September 30, 2029

Study Registration Dates

First Submitted

September 11, 2026

First Submitted That Met QC Criteria

September 16, 2026

First Posted (Actual)

September 22, 2026

Study Record Updates

Last Update Posted (Actual)

September 22, 2026

Last Update Submitted That Met QC Criteria

September 16, 2026

Last Verified

September 1, 2026

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe